Transforming growth factor-b1 (TGF-b1) is an important anti-inflammatory cytokine that modulates and resolves inflammatory responses. Recent studies have demonstrated that inflammation enhances neoplastic risk and potentiates tumor progression. In the evolution of cancer, pro-inflammatory cytokines such as IL-1b must overcome the antiinflammatory effects of TGF-b to boost pro-inflammatory responses in epithelial cells. Here we show that IL-1b or Lipopolysaccharide (LPS) suppresses TGF-b-induced anti-inflammatory signaling in a NF-kB-independent manner. TRAF6, a key molecule in IL-1b signaling, mediates this suppressive effect through interaction with the type III TGF-b receptor (TbRIII), which is TGF-b-dependent and requires type I TGF-b receptor (TbRI) kinase activity. TbRI phosphorylates TbRIII at residue S829, which promotes the TRAF6/TbRIII interaction and consequent sequestration of TbRIII from the TbRII/TbRI complex. Our data indicate that IL-1b enhances the pro-inflammatory response by suppressing TGF-bsignaling through TRAF6-mediated sequestration of TbRIII, which may be an important contributor to the early stages of tumor progression.
Introduction
Transforming growth factor-(TGF-b) is an important cytokine that plays fundamental roles in regulating cell proliferation, apoptosis, differentiation, and migration [1] . In the canonical signaling pathway, the TGF-b ligand directly binds to TbRII or TbRIII which, in turn, phosphorylates and activates TbRI. The activated TbRI recruits and phosphorylates Smad2 and Smad3 (R-Smads). These R-Smads form a complex with Smad4 which translocates into the nucleus to regulate TGF-b target genes [2] . TbRIII was originally described as an accessory receptor because it has no known enzymatic activity in its cytoplasmic domain and seemed to enhance TGF-b signaling by simply presenting TGF-b ligands to TbRII [3] . However, growing evidence indicates that TbRIII has a more complex role in the regulation of TGF-b signaling especially in cancer [4, 5] .
Aberrant TGF-b signaling, often caused by functional loss of key signaling components, is found in a broad range of cancers. Perturbation of TGF-b signaling, which most commonly results in a loss of its growth inhibitory function, provides a favorable condition for early-stage tumors to progress into malignant cancer. Therefore, it is important to identify the regulatory mechanisms of TGF-b signaling in the early stages of cancer development.
Persistent inflammation is closely linked to cancer progression through its stimulation of cell proliferation, survival, invasion, and metastasis [6, 7] . In normal tissue, inflammation induced by proinflammatory cytokines (e.g. IL-1b and TNF-a) is tightly regulated by anti-inflammatory cytokines (e.g. IL-10, IL-13, and TGF-b), which resolve the inflammatory response [8] . Therefore, it is essential to understand the mechanisms by which these two classes of cytokines function in a coordinate manner to maintain cellular homeostasis.
Pro-inflammatory mediators such as IL-1b and LPS activate NF-kB and p38/JNK pathways through the TRAF6/TAK1 axis. It is well established that IL-1b and TGF-b have antagonistically regulating mechanism towards one another. For example, TGF-b inhibits IL-1b signaling by disrupting the Pellino1/IRAK1 complex by Smad6 [9] , whereas TGF-b may block TNF-a signaling through the interruption of TRAF2/TAB2 and TAB3 association by Smad7 [10] . Conversely, pro-inflammatory cytokines are theorized to attenuate anti-inflammatory signals in order to enhance inflammatory responses. Indeed, it has been suggested that IL-1b and TNF-a exert suppressive effects on TGF-bmediated Smad2/3 phosphorylation and Smad3/4-DNA binding [11] . Also, IL-1b has been shown to inhibit Smad3-mediated TGF-b target gene activation through its downstream effecter TAK1 [12] . NF-kB/RelA-mediated Smad7 induction has also been suggested as a possible means by which cells suppress TGFb/Smad signaling [13] . Nonetheless, the underlying mechanism by which IL-1b attenuates anti-proliferative or apoptotic TGFbsignaling is not fully understood.
In this study, we demonstrate that IL-1bor LPS is able to suppress TGF-b/Smad signaling through regulation of the TGF-b receptor complex. We show that TRAF6 binds to TbRIII in a TbRI kinase-dependent manner, and thereby suppresses TGF-bSmad2/3 signaling.
Results and Discussion
IL-1b and LPS suppress TGF-b1-Smad2/3 pathways through TRAF6
In order to examine whether pro-inflammatory effectors (IL1b or LPS) are able to suppress Smad2/3-mediated TGF-b1 signaling, we treated various cells with TGF-b1 in the presence or absence of IL-1b or LPS. Co-treatment of cells with TGF-b1 and IL-1b resulted in decreased phospho-Smad2/3 in HEK293 ( Figure 1A ) as well as in other cell lines such as HaCaT, 67NR, and FaO cells ( Figure S1A , S1F, and S2A). We first examined whether TAK1, a key enzyme in pro-inflammatory signaling, is involved in IL-1b/LPS-mediated suppression of TGF-b signaling by using mutant TAK1 (K63W) which blocks IL-1b-mediated NF-kB activation ( Figure S1B ). TAK1 (K63W) failed to abrogate the IL-1b effect on TGF-b1/Smad signaling in SBE-luciferase reporter gene assay (SBE-Luc) containing promoter with Smadbinding sequences( Figure 1B ). It has been reported that NF-kBmediated Smad7 induction is one of the inhibitory mechanisms for TGF-b signaling [13] . However, one hour treatment with IL1b did not change the messenger RNA levels of SMAD7 in vector control, TRAF6, or TAK1 (K63W)-expressing cells ( Figure  S1C ). TRAF6 is an upstream molecule of TAK1 in IL-1b and LPS pro-inflammatory pathway, and we therefore investigated TRAF6 as a candidate molecule mediating the IL-1b-induced inhibitory effect. It is important to note that over-expressed TRAF6 may form self-associated and auto-ubiquitinated TRAF6, which is constitutively active, mimicking IL-1b or LPS stimulation [14, 15] . TRAF6 expression in HEK293 cells suppressed TGF-b1-induced Smad3 phosphorylation as compared tocontrol cells overexpressing GFP ( Figure 1C ). To find out if Smad7 is required for TRAF6-mediated suppression of Smad3 transcriptional activity, we performed SBE-luc reporter gene assay in HepG2 cells with knock-down of Smad7. The elevated SBE reporter activityin response to TGF-b represented effective knock-down of Smad7. Under this condition, TRAF6 was able to suppress SBE reporter activity by showing 65% and 70% reduction in control cells (pLKO) treated with TGF-b and Smad7 knock-down cells (shSmad7) treated with TGF-b, respectively. ( Figure S1D ). This finding implies that TRAF6 may similarly suppress TGF-b/Smad3 signaling even in the cells with reduced Smad7 expression. Near to complete knock-down of Traf6 was achieved in 67NR mouse mammary epithelial cells via infection with lentivirus encoding Traf6 specific shRNA. In sh-Traf6 cells, LPS-mediated suppression of Smad3 activity disappeared as compared to the control sh-Luc counterpart ( Figure S1E ), indicating that TRAF6 might be a factor responsible for mediating the suppressive effect of LPS on TGF-b1-mediated Smad3 phosphoryation. HaCaT cells, due to the sensitivity to TGF-b-induced cell growth inhibition, were used to examine whether TRAF6 overexpressing cells give rise to reduction of TGF-b1 target genes. The results of both quantitative PCR and RT-PCR indicated that TRAF6 overexpressing cells were less sensitive to TGF-b-mediated induction of the cell cycle inhibitors such as CDKN2B and CDKN1A and SMAD6 ( Figure 1D and Figure S1F ). These results further support the importance of TRAF6 as a critical mediator of IL1b-induced suppression on TGF-b signaling. The induction of apoptosis in rat hepatoma FaO cells by TGF-b is known to be mediated by active Smad2/3 [16] . Thus, the biological significance was addressed by examining the suppressive role of pro-inflammatory signaling on TGF-b-induced apoptosis in FaO cells. The TRAF6 over-expressing FaO cells were less sensitive to TGF-b-induced apoptosis as evidenced by decreased cleaved-caspase3 and Smad2 phosphorylation ( Figure 1E ). Induction of cleaved-caspase 3 and Smad3 phosphorylation by TGF-b1 were decreased in LPS co-treated cells ( Figure S2A ). To further investigate whether the LPS-induced inhibition of TGFb-induced apoptosis is dependent on NF-kB-mediated signaling, FaO cells were infected by adenovirus containing either LacZ or IkBaSR. IkBaSR is asuper-repressor mutant of IkBawhich cannot be phosphorylated or degraded by NF-kB-activating stimuli, and eventually prevents NF-kB transcriptional activation [17] . Induction of cleaved-caspase 3 by TGF-b1 was not affected in the presence of IkBaSR, indicating that NF-kB-dependent survival factors are less likely to play a role in this anti-apoptotic event ( Figure S2B ). Moreover, apoptotic induction by TGF-b was significantly suppressed by LPS co-treatment as demonstrated by TUNEL and DNA fragmentation assay ( Figure S2C and S2D). These results indicated that LPS may facilitate cell survival by suppressing Smad2/3 signaling pathways, possibly through TRAF6.
Traf6 2/2 primary cells showed elevated sensitivity to TGF-b1
The physiological function of Traf6 in TGF-b1-Smad2/3 signaling was further investigated in Traf6+/+ and Traf62/2 mouse embryonic fibroblasts (MEFs). Messenger RNA and protein expression of TGF-b receptors in Traf6+/+ and Traf62/2 MEFs appeared to be similar in both MEF cells ( Figure S3A ). When we examined the sensitivity to TGF-b using the SBE-luciferase assay, Traf62/2 MEFs showed stronger responsiveness to TGF-b than the Traf6+/+ MEFs ( Figure S3B ). The sensitivity to TGF-b was further examined by observing the dose-dependent responsiveness. Consistent with the reporter assay, Smad2 and Smad3 phosphorylation was detected at the lowest concentration of TGF-b1 (0.08 ng/ml) in Traf62/2 MEFs, and remained higher than that of wild-type MEFs at other elevated concentrations (Figure 2A ). In addition, nuclear translocation of Smad3 occurred at an earlier time point and with higher sensitivity to TGF-b1 in Traf6 2/2 MEFs ( Figure 2B) . A nuclei fractionation assay clearly showed that, upon TGF-b1 treatment, the level of nuclear translocation of Smad2 and Smad3 was elevated in Traf62/2 more than that of the Traf6+/+ MEFs ( Figure 2C ). To demonstrate the key role of Traf6 in LPS-induced suppression, we conducted TGF-b1/LPS co-treatment experiments using the MEF cells. Traf62/2 MEFs showed much stronger induction of pSmad3 by TGF-b1 treatment than that of Traf6+/+ MEFs, which is consistent with previous results ( Figure 2D ). Importantly, LPS-induced suppression of Smad3 phosphorylation was observed only in the Traf6+/+ MEFs as co-treated with TGF-b1/LPS, but not in the Traf62/2 MEFs, which implies that Traf6 is playing an inhibitory role for TGF-b signaling in non-transformed MEF cells.
TRAF6 forms a complex with TbRIII in a TGF-b1-dependent manner TbRIII is conventionally described as an accessory receptor that presents the TGF-b ligand to TbRII, thereby boosting TGF-b response [18] . However, recent studies demonstrate that TbRIII has additional roles in regulating receptor internalization through interaction with b-arrestin2, which is involved in terminating TGF-b1 signaling [5] . We confirmed that TbRIII interacts withbarrestin2 in a TbRII-and TGF-b-dependent manner ( Figure  S4A ). Interestingly, a recent study showed that b-arrestin1/2 interacts with TRAF6 and suppresses TRAF6-mediated proinflammatory responses [19] . Therefore, we explored the possibility that TbRIII is involved in TRAF6-mediated suppression of TGF-b signaling, probably through the common binding partner b-arrestin1/2. We first investigated the relationship between TRAF6 and TbRIII in regulating TGF-b-mediated gene induction by carrying out a CAGA12-Luc reporter gene assay containing promoter with 12 tandem repeats of Smad3 binding sequences. In cells expressing exogenous TbRIII, TGF-b-induced CAGA12-Luc activation was attenuated by IL-1b co-treatment ( Figure 3A) . TbRIII overexpression markedly enhanced TGF-b1 response, but TRAF6 dose-dependently inhibited TGF-b1 signaling, even in the presence of TbRIII ( Figure S5A and S5B). These results suggest that TbRIII plays a significant role in the integration of IL-1b into TGF-b signaling. Interestingly, when the importance of b-arrestin 1/2 was examined, the inhibitory effect of TRAF6 on TGF-b-induced SBE-Luc reporter activity was observed in b-arrestin1/2 2/2 MEFs ( Figure S4B ). This finding suggests that b-arrestin may not play a major role in TRAF6-mediated inhibition of TGF-b signaling. To determine how TbRIII expression affects TRAF6-mediated inhibition of TGF-b signaling, we generated a TbRIII knock-down HaCaT cell line by lentiviral knock-down system. RT-PCR results verified that TbRIII mRNA expression was almost completely blocked without any changes in TbRI and TbRII expression ( Figure S5C ). Interestingly, IL-1bfailed to suppress TGF-b1-induced Smad3 phosphorylation in the TbRIII knock-down HaCaT cells ( Figure 3B ). These results indicate that IL-1b may down-regulate TGF-b signaling through the interactions between TRAF6 and TbRIII proteins. To explore the possibility that the suppression of TGF-b signaling is mediated by enhancing TRAF6/TbRIII interaction, HA-TbRIII and Myc-TRAF6 were expressed in HEK293 cells and treated with TGF-b1 for up to 120 minutes and followed by co-immunoprecipitation assays. Myc-TRAF6 and HA-TbRIII were co-precipitated together only in the TGF-btreated cells with the most abundant association at 60 minute stimulation ( Figure 3C ), suggesting that activation of TGFbsignaling triggers the association between TRAF6 and TbRIII. Next, we tried to determine the importance of TRAF6 E3 ligase activity for the formation of a complex with TbRIII. As compared to wild-type TRAF6, the mutant TRAF6 (C85A/C87H), which has no E3 ligase activity, was unable to interact with TbRIII ( Figure 3D ). The interaction of TbRIII with TRAF6 was confirmed in the Duolink in situ proximity ligation assay (Olink PLA) which enables visualization and quantification of protein interaction when two proteins are at close proximity [20, 21] . HATbRIII-stable HEK293 cells were treated or untreated with TGFb for one hour and followed by immunodetection of endogenous TRAF6 and HA-tagged TbRIII in the OLink PLA. The signals from the proximally localized proteins are amplified as red dots in the OLink PLA. The number of TRAF6/HA-TbRIII complexes per cell was found to be significantly higher in the TGF-b1 treated cells (visualized as red dots in Figure 3E , quantitated in Figure 3F ). To test whether TRAF6 and TbRIII association is enhanced by activation of endogenous TRAF6, an HA-TbRIII stably expressing cell line was generated using the 4T07 mouse mammary tumor cell line. The 4T07 cells were used for this experiment because these cells express low to undetectable level of TbRIII which may allow better endogenous TRAF6 and HA-TbRIII interaction without major interference by endogenous TbRIII. TGF-b1 treatment induced interaction between TRAF6 and HA-TbRIII, but co-treatment of cells with LPS and TGF-b1 further enhanced the association of these proteins ( Figure 3G ). Decreased Smad2 phosphorylation in TGF-b1/LPS co-treated cells suggests that endogenous TRAF6 is involved in LPS mediated inhibition of the TGF-b1/Smad signaling pathway. This result clearly shows that activated TRAF6 migrates to the plasma membrane and avidly forms a complex with TbRIII upon TGF-b treatment.
Association of TRAF6/TbRIII is regulated by TbRII and TbRI kinase activity
Since the TRAF6/TbRIII complex formed only after TGF-b1 stimulation, we questioned whether TbRII and/or TbRI play a role in TRAF6/TbRIII complex formation. To test the potential TRAF6/TbRIII interaction's dependency on TBRII, SNU638 human gastric cancer cells, which do not express functional TbRII [22] , were used in a co-immunoprecipitation assay. TRAF6/ TbRIII complex formation was very weak in TGF-b1-treated cells in the absence of functional TbRII ( Figure 4A) ; however, TRAF6 binding to TbRIII was readily detected upon exogenous expression of TbRII and TGF-b1 treatment. Next, we investigated if TbRI is involved in the TRAF6/TbRIII complex formation in Tgfbr12/2 MEFs. Whereas trivial interaction of TRAF6/TbRIII was detected in the absence of exogenous TbRI expression, the perceptible association of TRAF6/TbRIII was induced 60 min post treatment of TGF-b1 only in Tgfbr12/2 MEFs expressing exogenous TbRI ( Figure 4B ). This finding implies that TbRI as well as TbRII activation by TGF-b is critical mechanism for the induction of TRAF6/TbRIII complex formation. Therefore, these results indicate that intact TbRII and TbRI expression are important for TRAF6 and TbRIII complex formation upon TGFb stimulation. To further elucidate the detailed mechanism, we examined whether TbRI kinase activity is required for TRAF6/ TbRIII interaction; this was examined by the use of wild-type TbRI, a kinase inactive form of TbRI (K232R; KR), and a constitutively active form of TbRI (T204D; TD), in coimmunoprecipitation assay. As anticipated, the constitutively active form of TbRI (TD) significantly enhanced the interaction between TRAF6 and TbRIII, whereas TbRI wild-type and TbRI (KR) showed respectively moderate and negligible levels of interaction ( Figure 4C ), suggesting that TbRI kinase activity is important for promoting the TRAF6/TbRIII association. This is further confirmed by demonstrating that the association of TRAF6/TbRIII was largely reduced in cells pre-treated with IN-1130, a TbRI-specific kinase inhibitor [23] (Figure 4D) . Additionally, the importance of the TbRI kinase activity was visualized and quantified using the Olink PLA. In the experiment, exogenous TRAF6 and HA-TbRIII were expressed in HEK293 cells and treated with TGF-b1 in the presence or absence of IN-1130. Then, cells were immunostained with anti-Myc (9E10) and anti-HA (Y11) to detect proximally located antigens. As a result, Myc-TRAF6 and HA-TbRIII co-localized in the TGF-b-treated cells, whereas IN-1130-treated cells showed negligible levels of signal, similar to untreated controls (Figs. 4E and 4F ). This result validates the importance of TbRI kinase activity in TRAF6 and TbRIII complex formation. Interestingly, there has been an observation that TRAF6 binds to TbRI via the TRAF6 consensus binding motif [24] . We therefore attempted to test whether the consensus binding motif for TRAF6 found on TbRI would affect the interaction between TRAF6 and TbRIII. We performed a coimmunoprecipitation assay with cells expressing TRAF6, TbRIII, and either TbRI (KR), TbRI (TD), or TbRI (TD-E161A), a TbRI with mutation of the TRAF6 consensus binding motif. TRAF6/ TbRIII interaction was mostly abrogated by the kinase-inactive TbRI mutant (KR), but only slightly decreased by the TRAF6 consensus binding motif mutant (E161A) of TbRI (TD) ( Figure 4G ). These results suggest that the TRAF6-TbRIII interaction occurs independently of the TRAF6-TbRI interaction.
TbRIII is a substrate of TbRI kinase
The cytoplasmic domain of TbRIII has been demonstrated for TbRII interaction and become phosphorylated when TbRII is over-expressed, leading to the dissociation of TbRIII from the TbRII/TbRI complex [25] . Therefore, we speculated that TbRI may be the Ser/Thr kinase that phosphorylates TbRIII upon TGF-b1 stimulation. HEK293 cells stably expressing TbRIII were treated with TGF-b1 for up to 120 minutes, and lysates were immunoprecipitated for HA-TbRIII. Phospho-TbRIII was assessed using a phospho-Serine-specific antibody ( Figure 5A ). The phospho-form of TbRIII was detected at maximum intensity at 60 minutes after TGF-b1 stimulation, which agreed with the results of TbRIII-TRAF6 interaction shown in Figure 3C . This prompted us to verify whether TbRI directly phosphorylates the cytoplasmic domain of TbRIII. We utilized GST protein-tagged deletion mutants for TbRIII cytoplasmic domain, as illustrated in Figure 5B . HA-TbRI (TD) was expressed in HEK293T cells and then immunoprecipitated with anti-HA antibody for an in vitro kinase assay. Consistent with our hypothesis, TbRI (TD) strongly phosphorylated the GST-tagged cytoplasmic domain of TbRIII and the TbRIII-835 mutant, but not the TbRIII-823 mutant ( Figure 5C ), implying that TbRIII possesses a potential phosphorylation site(s) for TbRI kinase between amino acids 823 and 835. The specific activity of the TbRI (TD) kinase in this assay was determined by addition of 1 mM IN-1130, which almost completely blocked not only auto-phosphorylation of TbRI (TD) but also ablated GST-TbRIII phosphorylation ( Figure 5C ). Next, to identify the exact phosphorylation site, we prepared GSTTbRIII-C proteins with point mutations at the four serine residues between amino acids 823-835 into alanine, respectively ( Figure 5B) , and then performed a TbRI (TD) kinase assay. As shown in Figure 5D , TbRI (TD) was able to phosphorylate GSTTbRIII-C and mutants S826A, S830A, and S834A, but was unable to phosphorylate mutant S829A, indicating that residue Ser 829 is a potential phosphorylation target of TbRI (TD). To determine whether phosphorylation of TbRIII may enhance the association of TbRIII with TRAF6, we performed a GST pulldown assay with TbRIII-C-GST fusion proteins that were unphosphorylated or phosphorylated by TbRI (TD) in vitro. TRAF6 strongly interacted with TbRIII-C activated by TbRI (TD) ( Figure 5E ). This result clearly showed that the TbRImediated TbRIII phosphorylation is a key mechanism of the TRAF6/TbRIII complex formation. To determine the minimal binding domain of TbRIII, we designed a GST pull-down assay with GST-TbRIII-C deletion mutants. While TRAF6 was able to bind TbRIII-C and the TbRIII-835 mutant phosphorylated by TbRI (TD), it could not bind the TbRIII-823 mutant in which the TbRI (TD)-induced phosphorylation site was deleted ( Figure 5F ). These results indicate that the TbRIII region between amino acids 823-835, phosphorylated by TbRI (TD), encompasses a site responsible for interaction with TRAF6. We therefore set up an Olink assay to demonstrate the requirement of TbRIII S829 phosphorylation for interaction with TRAF6. In the Olink proximity ligation assay, the interaction between TRAF6 and TbRIII (S829A) was weak and unchanged in response to TGF-b (Figs. 5G and 5H ). These results indicate that TbRIII is a novel substrate of TbRI kinase, and that the phosphorylation of TbRIII at S829 by acitivated TbRI kinase is playing a major role for TRAF6/TbRIII interaction.
TRAF6 dissociates TbRIII from TbRII/TbRI complex
In order to elucidate the underlying mechanism by which TRAF6 suppresses TGF-b/Smad signaling through the association with TbRIII, we hypothesized that TRAF6 may disrupt TbRIII/TbRII complex formation, which is critical in boosting cellular TGF-b1 responses [18] . We found that exogenous expression of TRAF6 interrupted TGF-b1-induced TbRIII and TbRII interaction ( Figure 6A) . Furthermore, the level of TbRII bound to TbRIII was inversely related to the level of TRAF6 expression ( Figure 6B ). The physiological significance of the influence of TRAF6 on TGF-b signaling was determined by examining endogenous TRAF6 bound to TbRIII in cells treated with TGF-b1 alone or with IL-1b. In the TGF-b1-treated cells, TbRIII/TbRII association persisted up to 60 minutes ( Figure 6C ). However, in the cells treated with both TGF-b1 and IL-1b, the level of TbRIII-bound TbRII decreased close to the basal level, while the level of TbRIII-associated TRAF6 increased at 60 minutes. We observed the interaction between TbRIII and endogenous TRAF6 in cells treated with only TGF-b (Figure 3G and 6C), which may not be enough to dissociate TbRIII from TbRII complex ( Figure 6C ). The dissociation is likely to occur only in the case of abundant association of TRAF6 to TbRIII upon LPS or IL-1b co-stimulation ( Figure 6C ). Taken together, our study suggests a model in which simultaneous treatment with IL-1b/LPS and TGF-b1 provokes robust interaction between TRAF6 and TbR complex while TGF-b alone induces mild interaction of these molecules. Subsequently, IL-1b or LPS suppresses TGF-b/Smad signaling by increasing an interaction between TRAF6 and TbRIII, which is dependent on active TbRImediated phosphorylation of TbRIII at Ser829 ( Figure 6D ). This interaction between TRAF6 and TbRIII is possibly resulted from dissociation of TbRIII from the TbRII/TbRI complex, thereby contributing to the down-regulation of Smad2/3-dependent cellular responses.
Here we have demonstrated that TRAF6, activated by IL-1b or LPS, suppresses TGF-b1/Smad pathways through interaction with TbRIII upon TGF-b1 stimulation. In general, inflammation is tightly regulated and resolved by the induction of antiinflammatory cytokines [8] . Once this regulatory balance is disturbed, non-specific stimulation and activation of inflammatory cells may lead to increased production and release of potently destructive immunological and inflammatory molecules. TGF-b1 is a pleiotropic cytokine with considerable anti-inflammatory properties. Deficiency of TGF-b1 signaling in the intestine contributes to the development of inflammatory bowel disease, suggesting that maintenance of TGF-b1 signaling is important in regulating immune homeostasis in the intestine [26, 27] . It is well known that inflammatory bowel diseases predispose cancer formation in the intestinal tract. The increased and persistent pro-inflammatory cytokines in the tumor microenvironment play a major role for inducing malignancy [6, 7, 8] . For instance, improper regulation of IL-1b signaling has been shown to potentiate neoplastic risk and ultimately induce tumor progression [8] . In fact, polymorphisms of IL1B promoter which enhance IL1b expression are associated with increased risk of developing human gastric cancer [28, 29] . The study performed in IL-1b knock-out mice suggested that IL-1b enabled local tumor growth and/or metastasis to the lung [30] . In addition, decreased TbRIII expression was closely correlated with tumor progression in various human cancers including breast, lung, prostate, pancreatic, ovarian, and renal cancers [31] , supporting the idea that TbRIII-mediated regulation of normal epithelial cells may contribute to prevent tumor progression.
A recent report also showed that Traf6 inhibits Th17 T cell differentiation through the downregulation of Smad signaling [32] . Although the detailed mechanism of this inhibition has not been elucidated in T cells, it supports that Traf6 is partly responsible for inhibiting the TGF-b-induced Smad2/3 signaling pathway in vivo. Thus, constitutive activation of TRAF6 by abundant IL-1b in the lesion may contribute to the early stages of tumor development, at least in part, via inhibition of Smad2/3 tumor suppressor pathway.
It is suggested that TRAF6 interacts with TbRI/TbRII complex upon stimulation of TGF-b and mediates activation of p38/JNK MAPKs via TRAF6/TAK1 axies without inhibition of Smad2/3 signaling [24, 33] . We observed that TRAF6 involved in the dissociation of TbRIII from TbRII/I complex in a dose-dependent fashion ( Figure 6 ) and interaction of TRAF6/TbRIII was increased in LPS/TGF-b co-treated cells ( Figure 3G ). These results suggest a model in which TRAF6 may differently regulate TGF-b-induced Smad2/3 and/or p38/JNK activation depending on the amount of TRAF6 interacting with TGF-breceptor complex. These regulatory mechanisms are potentially important to determine TGF-b responses such as cell growth arrest, apoptosis, or epithelial-mesenchymal transition.
In summary, our data delineated a key molecular mechanism that IL-b or LPS inhibits anti-inflammatory TGF-b/Smad signaling through TRAF6 and TbRIII association in TGF-band TbRI kinase-regulated manner. Although the antagonistic effects of IL-1b/LPS on TGF-b1 signaling may occur at multiple molecular levels, a fine modulation of the TGF-b receptors may critically affect cell fates by changing the kinetics of Smad2/3 phosphorylation. By this mechanism, IL-1b may potentiate inflammatory responses, and chronic inflammation may further contribute to tumor progression by suppressing the TGF-b antiinflammatory and tumor suppressor pathways.
Materials and Methods

Cell culture and reagents
HepG2, HEK293, HEK293T, 67NR, 4TO7, and 4T1 cells were obtained from ATCC and HaCaT cells were kindly provided by Dr. Stuart Yuspa (National Cancer Institute, Bethesda, MD). TRAF6-deficient mouse embryonic fibroblasts and b-arrestindeficient MEFs were gifted from J. Inoue (Keio University) and R. Lefkowitz (Duke University), respectively. FaO cell were also kindly gifted by Dr. I. Lim (Aju university). HaCaT, HepG2, FaO, HEK293, and HEK293T cells were grown in DMEM, and 67NR and 4T07 breast cancer cell lines were grown in RPMI supplemented with 10% (vol/vol) FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml; Invitrogen, Rockville, MD). Cells with stable expression of TbRIII were generated by transfection with pCDNA3.1-HA-TbRIII and then selected as a pool in selection medium containing neomycin. Antibodies specific for hemagglutinin (Y-11 or F-7), Myc (9E10), TRAF6 (H-274), TbRII (C-16), and TbRI (V-22) were purchased from Santa Cruz; antibodies to Flag (anti-Flag; M2) and anti-b-actin (AC-15) were from Sigma; specific antibodies for p-Smad2, p-Smad3, and total Smad2 were from Cell Signaling; anti-Smad3 and anti-phosphoserine specific antibodies were from Zymed Laboratories.
TUNEL assay
TGF-b-induced cell death in FaO cells was demonstrated using In Situ Cell Death Detection Kit Fluorescein (Roche) according to manufacturer's protocols, which can detect single-and doublestranded DNA breaks that arise at early stages of apoptosis.
DNA Fragmentation assay
Following treatment of FaO cells with TGF-b and/or LPS for overnight, all of the adherent and floating cells were collected and subjected to genomic DNA preparation. The collected cells were resuspended in 400 ml extraction buffer (0.5% SDS, 0.1 M NaCl, 0.01 M EDTA, 0.02 M Tris-HCl (pH 7.6), and proteinase K (100 mg/ml)) and followed by incubation at 60uC for 2 hours. The lysates were resuspended with 200 ml of 6 M NaCl, mixed thoroughly, and placed on ice for 5 minutes. After spin down the lysates for 10 minutes at 13,000 rpm, the 400 ml supernatants were transferred and mixed with 100% ethanol to precipitate genomic DNA. The precipitated DNA was harvested and dissolved in TE buffer. Finally, the DNA was incubated for 1-2 hours at 56uC, and measured DNA concentration and loaded in 1% agarose gel with equal amount of genomic DNA.
Immunofluorescence microscopy
Wild-type and Traf6-deficient MEF cells were grown on 22-mm glass coverslips in a CO 2 -humidified incubator for 24 h. Smad3 was detected by incubation at 4uC with anti-Smad3 rabbit polyclonal (Zymed Laboratories Inc.). The images were acquired with Nikon microscope by using MetaMorph software.
Nuclear fractionation and quantification
Nuclear and cytoplasmic fractionations were performed according to previously described methods [34] . Density of detected Smad2 and Smad3 was quantitated using ImageJ software and marked as a fold change.
Knock-down and over-expression using Lentiviral infection system
Knockdown of endogenous Traf6 and TbRIII gene expression was carried out using the lentivirus shRNA expression system and experimental method as previously described [10] . The target sequence of mouse traf6 nucleotide 618-637 (AGCTGTCCTCT-GGCAAATATC), human TGFBR3 nucleotide 1878-1897 (ATG-GTGTGGTCTACTATAA), or control Luciferase nucleotide was used. For over-expression, the TRAF6 gene was introduced into pCAG-MCS-W Lentiviral vector and transfected for viral packaging.
In vitro site-directed mutagenesis
In order to generate mutant constructs (S826A, S829A, S830A, and S834A) for C-term of TbRIII (TbRIII-C), we performed in vitro site-directed mutagenesis reaction by employing QuickChange Site-directed mutagenesis kit (Stratagene). We designed specific primers for each mutant construct (supplementary data) according to the manufacturer's protocol.
In Vitro Kinase Assay
The TbRI kinase assay was performed as described [23] and GST-TbRIII deletion mutant proteins were prepared according to the manufacturer's protocol (Amersham Bioscience). The truncation mutants of TbRIII-835 and TbRIII-823 were generated by introducing termination codon, according to the instruction of sitedirected mutagenesis kit (Stratagene). The phospho-labeled proteins were detected by autoradiography.
Proximity ligation assay (PLA)
PLA was performed to visualize protein-protein interactions using the reagent kit from Olink Bioscience. In brief, oligonucleotide conjugated 'probe' antibodies are directed against primary antibodies. Annealing of the 'probes' occurs when the target proteins are in close proximity, which initiates the amplification of a Texas red reporter signal [21] . After TbRIII-myc and TRAF6-myc transfection, HEK 293T cells were treated with TGF-b1 for 1 hr , 0.1 mM IN-1130 for 2 hr. Cells were washed with chilled PBS and fixed with acetone for 20 mins, and incubated overnight with mouse anti-myc (1:100, Santa Cruz, sc-40) and rabbit anti-HA (1:100, Santa Cruz, sc-805) at 4uC. Proximity ligation was performed according to the manufacturer's protocol using the Duolink Detection Kit with PLA PLUS and MINUS Probes for mouse and rabbit (Olink Bioscience). Hoechst stain was included in the Duolink Detection Kit while antirabbit Alexa 488 (1:500; Invitrogen Inc.) was added during the detection reaction. Specimens were mounted with Vecta-shield mounting media (Vector Laboratories) and examined with and confocal microscope (Carl Zeiss, LSM 710). The number of in situ PLA signals per cell was counted by semi-automated image analysis using the freeware software BlobFinder V 3.0. 
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